Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.70bn
- Net income in CHF573.00m
- Incorporated2002
- Employees17.83k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Mergers & acquisitions
| Acquired company | LONN:SWX since announced | Transaction value |
|---|---|---|
| Genentech Inc-Biologics Manufacturing Facility,Vacaville,California | 8.96% | 1.20bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 1.74bn | 82.42m | 8.41bn | 5.90k | 103.24 | 2.65 | 31.36 | 4.82 | 0.3896 | 0.3896 | 8.40 | 15.17 | 0.3229 | 2.03 | 5.71 | 314,627.40 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 2.46bn | 577.68m | 11.93bn | 2.64k | 20.28 | 2.88 | 32.23 | 4.85 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 1.65bn | -35.73m | 31.58bn | 1.15k | -- | -- | -- | 19.16 | -0.802 | -0.802 | 29.19 | -- | -- | -- | -- | 1,545,967.00 | -- | -17.65 | -- | -19.79 | 89.56 | -- | -2.17 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| Lonza Group AG | 6.70bn | 573.00m | 37.67bn | 17.83k | 65.73 | 3.90 | 33.10 | 5.63 | 7.94 | 7.94 | 92.53 | 133.83 | 0.3767 | 2.60 | 4.35 | 372,000.00 | 3.23 | 5.07 | 3.81 | 6.21 | 29.21 | 39.15 | 8.57 | 14.52 | 1.38 | 5.14 | 0.2873 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 05 Nov 2024 | 2.73m | 3.79% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.41m | 3.34% |
| Norges Bank Investment Managementas of 10 Sep 2024 | 2.17m | 3.00% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.28m | 1.77% |
| BlackRock Investment Management (UK) Ltd.as of 14 Nov 2024 | 1.28m | 1.77% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Sep 2024 | 1.16m | 1.61% |
| Invesco Advisers, Inc.as of 07 Nov 2024 | 933.28k | 1.29% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 931.51k | 1.29% |
| Comgest SAas of 31 Jul 2024 | 708.50k | 0.98% |
| Geode Capital Management LLCas of 14 Nov 2024 | 707.68k | 0.98% |
